Blog

Updates for the week of November 24–28, 2025, are headlined by a major intervention from WHO Europe on AI safety, fresh capital for Nordic oncology innovation, and significant new regulatory guidance from the UK's MHRA.1. Top Story: WHO Europe's "Fork in the Road" for AI Wednesday, Nov 26 – The World Health Organization (WHO) Regional Office for Europe released a landmark report on artificial intelligence in healthcare, urging immediate government action.The Warning: The report warns that European healthcare stands at a critical "fork in the road." Without stronger legal safeguards, the rapid deployment of AI tools risks "entrenching inequalities" and compromising patient safety.Key Findings: The review of 50 member states found that while 66% are already using AI for diagnostics (imaging/detection), only 8% (4 countries) have a dedicated national strategic framework for AI in health.Implication: This report is expected to accelerate national-level legislation across the EU to plug these "governance gaps" before the full implementation of the EU AI Act. 2. Investment: Fresh Capital for Nordic Oncology Thursday, Nov 27 – In a week otherwise quiet for "mega-deals," a significant Seed round in Finland highlighted the continued investor appetite for clinical-grade AI.&nbsp;The Deal: Helsinki-based Gosta Labs raised €7.5 million in an oversubscribed Seed round led by deep-tech investor Voima Ventures.The Tech: Unlike general administrative AI, Gosta Labs is building an "AI operating system" specifically for oncology. The platform is designed to handle the extreme complexity of cancer care documentation and decision support, aiming to free up clinician time.&nbsp; &nbsp; Trend: This deal reinforces a key 2025 trend: investors are moving away from generic "health AI" toward highly specialized, vertical-specific solutions that tackle high-burden disease areas like cancer. 3. Regulation: MHRA Updates Digital Mental Health Rules Monday, Nov 24 – The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) issued updated guidance for Digital Mental Health Technologies (DMHTs).New Focus: The updates specifically address "identifying and reporting harms" and "user perspectives." Why it Matters: As prescription digital therapeutics (PDTs) for mental health proliferate, the MHRA is tightening the loop on post-market surveillance. The new guidance clarifies how manufacturers must categorize and report adverse events (e.g., if a chatbot gives unsafe advice or a VR therapy causes physical side effects), signaling a mature regulatory approach to "software as a medical device" (SaMD).&nbsp; 4. Strategic Analysis: The "Digital Omnibus" Reaction While the European Commission's "Digital Omnibus" proposal (aiming to delay high-risk AI rules for medical devices) was unveiled late last week, this week saw the industry formally digest the news.Industry Stance: MedTech Europe officially welcomed the proposal this week but urged policymakers to go further. They are pushing for a "targeted postponement" of MDR re-certification requirements to avoid a bottleneck in 2027/2028, arguing that the AI delay alone solves only half the problem.&nbsp; &nbsp; Market Sentiment: Analysis published this week suggests the "dual burden" of MDR and the AI Act has effectively paused many R&amp;D pipelines, and this proposed delay is now factored into 2026 strategic planning for major European device manufacturers.&gt;&gt;&gt;Updates from the week of November 24–28, 2025, highlight a significant shift in the regulatory landscape for European MedTech, alongside major investment news and post-conference analysis from MEDICA 2025.1. Top Story: The "AI Act Pause" &amp; Digital Omnibus The most critical strategic development discussed this week is the European Commission's proposal to delay specific "high-risk" AI rules for medical devices.&nbsp;The Proposal: As part of the Digital Omnibus package (officially unveiled Nov 19 but dominating industry strategy this week), the Commission proposed a targeted delay of up to 16 months for the enforcement of high-risk AI obligations.Why it Matters: MedTech associations have fiercely lobbied for this, citing the "dual burden" of complying with both the Medical Device Regulation (MDR) and the new AI Act. This delay is designed to give manufacturers breathing room to align technical standards without stalling innovation or market access.Impact: This week, industry analysis has focused on how this "pause" will allow companies to re-evaluate their R&amp;D timelines for AI-driven diagnostic and surgical tools for 2026. 2. Investment: Major Capital for European Innovation Despite a generally tight funding environment, a massive capital injection has signaled renewed investor confidence in the sector.Sofinnova Partners Closures Fund XI: Paris-based VC firm Sofinnova Partners finalized its "Capital XI" fund at €650 million.Focus: The fund is specifically targeted at early-stage HealthTech and MedTech companies (along with biotech).Significance: This is one of the largest early-stage healthcare funds in Europe recently, offering a critical lifeline to startups facing the "Series A crunch" and aiming to keep deep-tech innovation within Europe.Regional Funding: Finnish startup Gosta Labs raised €7.5 million this week to advance its AI-driven oncology platform, highlighting the continued investor appetite for AI solutions that improve clinical workflow efficiency.&nbsp;3. Regulatory &amp; Product Approvals EC Approves First Non-CF Bronchiectasis Treatment: The European Commission granted marketing authorization for Brinsupri (brensocatib). This is the first approved treatment in the EU for non-cystic fibrosis bronchiectasis, marking a major milestone for patients with this chronic lung condition.UK MHRA Updates: The UK regulator (MHRA) issued new guidance this week on digital mental health technologies, securing £2 million in funding (jointly with NICE) to develop clearer regulatory pathways for these tools.4. Market Moves &amp; Innovation (Post-MEDICA) Following the conclusion of MEDICA 2025 in Düsseldorf (Nov 17–20), this week has been defined by the industry "digesting" key announcements:European Robotics Challenger: Industry talk has centered on Amplitude Surgical (a subsidiary of Zydus Lifesciences), which recently received the CE Mark for its "Andy" orthopaedic robotic system. This positions a verified European competitor against established US players (like Stryker or Zimmer Biomet) in the knee and hip surgery market.&nbsp; Hospital 4.0 Focus: A key theme emerging from the conference reviews this week is "Hospital 4.0"—specifically the shift from hardware-focused purchasing to software-integrated ecosystems that connect patient monitoring, diagnostics, and electronic health records.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk﻿</a>

This Week in European HealthTech and MedTech: 28th November 2025

The latest UK Budget and related announcements today are directionally positive for UK healthtech and medtech, but the upside is concentrated around NHS digitisation, data and regulatory reform rather than big new cash for StartUps and ScaleUps.Headline: £300M NHS Tech BoostThe Budget commits an extra £300M of capital for NHS technology, on top of an already large multi‑year digital spend, to modernise infrastructure and boost productivity. This money is earmarked for things like upgrading the NHS App, improving access to digital health records, and automating admin, which creates more receptive “pull” from the NHS for proven digital tools rather than direct subsidies to vendors.​For healthtech companies selling workflow tools, remote monitoring, AI triage, EPR add‑ons, and integration solutions, this means a slightly bigger near‑term market and clearer demand signals, particularly if they can plug into national platforms and standards. However, the funding is modest against the scale of NHS IT needs, so competition for procurement slots will be intense and favours vendors with interoperability, security credentials, and strong outcomes data.​Life Sciences and R&amp;D signalsBeyond frontline NHS IT, the Spending Review and wider life sciences plans confirm substantial medium‑term R&amp;D budgets: UKRI is allocated £38.6bn over 2026–2030 and the Office for Life Sciences receives over £900m, alongside a pledge of up to £22.6bn a year of public R&amp;D by 2029/30. For medtech and deep healthtech (e.g., diagnostics, devices, AI algorithms), this underpins continued grant and collaborative funding opportunities rather than radical new schemes.​Industry bodies still warn that private investment conditions lag global competitors, calling for stronger incentives for innovative medicines and technologies to reverse falling R&amp;D inflows. Practically, this means companies should see public co‑funding and academic collaboration remain available, but cannot assume the Budget alone will transform the UK into a top‑tier scale‑up capital market without additional tax and pricing reforms.​Regulatory and market access reforms On the medtech side, MHRA proposals point to friendlier, more flexible regulation: indefinite recognition of CE‑marked devices for GB, streamlined labelling, and reliance on trusted foreign regulators, which particularly helps SMEs by cutting duplicative approval costs. A new “Early Access” scheme lets innovative devices addressing unmet needs into NHS use before full regulatory approval, initially focused on diagnostics and urgent NHS priorities.​Together with work on an integrated, rules‑based medtech pathway and a pause on expanding the MedTech Funding Mandate while this is developed, the direction is towards clearer, faster routes from evidence to reimbursement, but with some short‑term policy limbo. Companies that invest in robust clinical and economic data, align with NHS priority pathways (e.g., diagnostics, capacity‑releasing tech), and engage early with MHRA and NICE are best positioned to benefit from this shift.​What this “really” means for companiesFor UK healthtech (software, data, AI):Expect more procurement anchored around interoperability with the NHS App, shared care records, and national data standards, not one‑off pilots.​ Products that tangibly increase throughput or reduce admin burden will be favoured, as the Treasury is explicitly linking digital spend to measurable productivity and waiting‑time reductions.​ For UK medtech (devices, diagnostics):Regulatory friction should gradually fall, with CE recognition and Early Access routes lowering time and cost to first NHS use, especially for SMEs and novel diagnostics.​ However, with no major new dedicated adoption budget and a hold on expanding the MedTech Funding Mandate, commercial success will still depend on fitting into constrained NHS capital and tariff envelopes.​ Strategic moves founders should consider Pivot offerings and messaging around capacity and productivity gains in high‑pressure pathways (elective surgery, imaging, chronic disease management) that match Budget rhetoric and NHS priorities.​Build routes that integrate with national platforms (NHS App, shared care records, federated data environments) to tap the £300M tech spend rather than trying to sell standalone silos.​ For medtech, design regulatory and evidence plans around MHRA’s evolving pathways and Early Access diagnostics focus, using CE recognition and international reliance to accelerate multi‑market launches.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

What does today's Budget really mean for UK HealthTech and MedTech companies?

Left Shift: 2026 NHS IT Market OpportunitiesFuture Health Intelligence Market Insight Webinar<a data-mce-href="https://futurehealthintelligence.com" href="https://futurehealthintelligence.com" title="https://futurehealthintelligence.com" target="_blank" rel="noopener">https://futurehealthintelligence.com</a> &nbsp; Join Future Health Intelligence for an end of year market insight webinar to review the key changes that have shaped 2025 and to gain insights into the key trends that will drive the NHS and UK health IT market in 2026 and beyond, identifying the key emerging market opportunities from the three left shifts set out in the NHS 10-year Plan: Fit for the Future. &nbsp; &nbsp; We’ll also be examining what are the key trends shaping the wider UK HealthTech sector, with special guest Lloyd Price from Nelson Advisors, one of the UK’s leading HealthTech M&amp;A Advisors joining the webinar to look at key trends that have shaped 2025 and what is expected to be driving the market in 2026. &nbsp; The coming 2026-27 NHS financial year will be first year that significant investment from the £10 billion committed in Spending Review 2025 will begin to land.&nbsp;What market segments are likely to be the beneficiaries from new investment?What are the key timelines of national procurements of new platforms?How will Front Line digitisation evolve in 2026-27NHS digital maturity trends and emerging opportunitiesThe webinar will also provide attendees with insights on trends from the latest NHS IT budgets and investments, procurement activity trends and predictions for the next 12 months. &nbsp; The webinar will be led by Jon Hoeksma, founder FHI, and Lloyd Price partner at Nelson Advisors.<a data-mce-href="https://futurehealthintelligence.com" href="https://futurehealthintelligence.com" title="https://futurehealthintelligence.com" target="_blank" rel="noopener">https://futurehealthintelligence.com</a>

Nelson Advisors invited to join the Future Health Intelligence Market Insight webinar as the Guest Speaker

Nelson Advisors Partner Lloyd Price has been invited to Chair the Health Data and Cyber Security panel at Health Tech Forward 2025 in Barcelona. &nbsp;&nbsp; Health Data Under Attack: Emerging Vulnerabilities in Healthcare The healthcare sector faces a rapidly escalating threat landscape, with data breaches and cyberattacks becoming more frequent, sophisticated, and impactful. The vulnerabilities are often a combination of persistent issues and newly emerging threats.. Some of the key themes expected to be discussed on the panel include: &nbsp;&nbsp; 1. Ransomware and Extortion Attacks &nbsp;&nbsp; Ransomware remains the single most significant threat, often leading to service disruption and data theft. &nbsp;&nbsp; 2. Third-Party and Supply Chain Risk &nbsp;&nbsp; The reliance on an interconnected ecosystem of vendors, business associates, and technology partners has created a major security blind spot. &nbsp;&nbsp; 3. Exploitation of Network and Edge Devices &nbsp;&nbsp; Vulnerabilities in critical network infrastructure are being rapidly exploited by threat actors. &nbsp;&nbsp; 4. Human Factors and Phishing Innovation &nbsp;&nbsp; While not new, social engineering tactics continue to be the most common initial access vector, and they are becoming more advanced. &nbsp;&nbsp; 5. Internet of Medical Things (IoMT) and Legacy Systems &nbsp;&nbsp; The blend of old and new technology in clinical settings creates unique security challenges. &nbsp;&nbsp; 6. Geopolitical and Nation-State Threats &nbsp;&nbsp; Cyber adversaries linked to hostile nation-states are increasingly interested in the healthcare sector for espionage, revenue generation, and disruption. &nbsp;&nbsp; Health Tech Forward 2025 &nbsp;&nbsp; Conference Name: Health Tech Forward 2025 Location: Palau de Congressos de Barcelona in Barcelona, Spain. Dates: December 3-4, 2025. Focus: Europe's premier event for health tech innovation and investment, featuring keynote speeches, dynamic panel discussions, and targeted 1:1 networking opportunities. Panel Topic Context: The panel falls under the track/topic of cybersecurity, compliance, and collaboration(often referred to as the "3C's"), addressing the critical security challenges facing the healthcare sector as it adopts new technologies. &nbsp;&nbsp; The conference agenda often covers themes ranging from AI insights and clinical breakthroughs to consumer tech &amp; wellness. &nbsp;&nbsp; <a data-mce-href="https://healthtechforward.com" href="https://healthtechforward.com" title="https://healthtechforward.com" target="_blank" rel="noopener">https://healthtechforward.com</a>

Nelson Advisors invited to Chair the Health Data and Cyber Security panel at Health Tech Forward 2025 in Barcelona

Russian old wooden abacus made of black and white pebbles and beige frame on dark green background in the center top view

As of November 2025, the HealthTech M&amp;A market has stabilized following the recalibration of 2023–2024. While we are not seeing the "growth at all costs" valuations of 2021, multiples have recovered for high-quality assets. The primary theme for late 2025 is selectivity. Buyers (both strategic and Private Equity) are deploying capital aggressively but only for companies with proven unit economics, clear paths to profitability, or "must-have" AI infrastructure.1. Current Valuation Multiples (November 2025) The spread between "average" and "premium" assets has widened significantly. Companies with proprietary AI or strong recurring revenue (SaaS) command the highest premiums.Revenue Multiples (EV / LTM Revenue)Premium AI &amp; Data &gt; 6.0x – 8.0x+ &gt; Companies with proven proprietary algorithms (not just wrappers) or clean, actionable data sets (e.g., drug discovery, imaging AI).Value-Based Care Tech &gt; 5.5x – 7.0x &gt; Platforms enabling risk-bearing models (e.g., population health, remote monitoring).Telehealth (Hybrid) &gt; 5.0x – 7.0x &gt; Mature platforms with hybrid (virtual + in-person) capabilities. Pure-play telehealth sees lower multiples.General HealthTech &gt; 4.0x – 6.0x &gt; The "standard" range for growing digital health SaaS with average retention/margins.Unprofitable/Early Stage &gt; 3.0x – 4.0x &gt; Startups with high burn rates or unclear ROI are seeing significant valuation compressionCurrent market intelligence suggests the following HealthTech M&amp;A landscape for November 2025.EBITDA Multiples (EV / LTM EBITDA) Used for mature, profitable companies and tech-enabled services.Profitable HealthTech &gt; 10x – 14x &gt; Established software firms with &gt;20% EBITDA margins.Tech-Enabled Services &gt; 10x – 12x &gt; Service-heavy models (RCM, provider services) that scale slower than pure software.Broader Healthcare &gt; ~12.8x &gt; Median across the wider healthcare sector (hospitals, services, devices).2. The 4 Variables Driving Valuations Now If you are looking to understand why one company trades at 4x and another at 8x, it comes down to these four variables:A. The "AI Premium" (Reality vs. Hype)&nbsp;In 2025, buyers have moved past the hype phase. You don't get a premium just for saying "GenAI."Driver: Buyers are paying up for workflow integration. Does the AI actually reduce administrative burden or improve diagnostic accuracy today? Impact: Validated AI solutions in diagnostics, drug discovery, and RCM (Revenue Cycle Management) are seeing the highest multiples (often 8x+ revenue). B. Path to Profitability (Rule of 40) The "growth at all costs" era is definitively over.Driver: Private Equity (PE) firms—who are sitting on record "dry powder"—are prioritizing the "Rule of 40" (Growth % + Profit Margin % &gt; 40). Impact: Companies burning cash without a clear 12-18 month path to break-even are seeing offers with heavy structures (earn-outs) or significantly compressed multiples (3x revenue). C. The Value-Based Care (VBC) "Enablers" Healthcare is still shifting from Fee-For-Service to Value-Based Care.Driver: Payers and large Health Systems are desperate for tech that helps them manage risk and patient populations outside the hospital walls. Impact: Tech that proves it can lower cost of care (e.g., Remote Patient Monitoring, Chronic Disease Management) commands a premium because it directly impacts the buyer's bottom line. D. Regulatory &amp; Political Clarity Driver: With the 2024 US election cycle in the rearview, regulatory pathways for digital health (particularly AI and reimbursement codes) have stabilised.Impact: This reduced uncertainty has encouraged large strategic buyers (Pharma, MedTech) to resume "mega-mergers" and consolidation plays. 3. Notable HealthTech Deal Activity (2025 Examples) The market has seen a resurgence of "Platform" deals—large strategic acquisitions designed to build dominant positions in specific verticals.Johnson &amp; Johnson acquires Intra-Cellular Therapies ($14.6B): Bio-Pharma Tech. Highlights the massive premium paid for late-stage, de-risked assets in the central nervous system space.Clearlake Capital acquires ModMedicine ($5.3B): Practice Management SaaS. A classic PE play for a mature, profitable "system of record" widely used by specialty practices. Stryker acquires Inari Medical ($4.9B): MedTech. Demonstrates the continued appetite for medical devices that offer minimally invasive solutions with clear reimbursement pathways. Optum acquires Amedisys ($3.9B): Home Health / Tech-Enabled Services. (Note: Heavily scrutinised by regulators). Signals the continued push by payers to own the "home" setting of care. Roper Technologies acquires CentralReach ($1.9B): Behavioral Health SaaS. Highlights the strong demand for vertical-specific software, specifically in the autism/behavioral health space. 4. Sub-Sector Snapshot Provider Tech (RCM &amp; IT): Stable. Hospitals are squeezed financially, so they are buying tech that automates back-office tasks (RCM) to save money. High volume of deals, moderate multiples.Life Sciences IT (Drug Discovery): Bullish. Pharma giants facing patent cliffs are aggressively buying AI-driven drug discovery platforms to speed up R&amp;D.Digital Health (Consumer/Telehealth): Bearish / Mixed. The "Direct-to-Consumer" model is struggling with high customer acquisition costs. Valuation multiples here remain depressed unless the company has pivoted to B2B (selling to employers/payers).To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

HealthTech M&A Multiples November 2025: Current Trends and Variables driving valuations

Hello November. Desk calendar for planning November 2025.

Key developments in the European MedTech sector for the week of November 21st 2025, have been dominated by major regulatory shifts regarding AI, significant capital injections, and activity surrounding two major industry conferences.1. Regulatory &amp; Policy: The "AI Act Pause" ProposalThe most significant strategic development this week is the European Commission's proposal to delay the enforcement of "high-risk" AI rules for medical devices. The News: As part of a new "Digital Omnibus" package introduced this week, the Commission has proposed a "targeted implementation delay" for the EU AI Act. Impact: This would effectively pause the enforcement of strict obligations for high-risk AI systems (which includes many AI-driven medical devices) that were set to apply from August 2026. Why it matters: MedTech industry groups have been lobbying for this, arguing that the "dual regulatory burden" of complying with both the Medical Device Regulation (MDR) and the new AI Act would stifle innovation. If passed, this gives manufacturers a critical breathing room of up to 16 months to align their technical standards. 2. Investment &amp; FundingA €650M Boost Despite a generally difficult fundraising climate, this week saw a massive commitment to the European life sciences ecosystem.Sofinnova Partners closes Capital XI: The Paris-based venture capital firm announced the final close of its "Capital XI" fund at €650 million ($750M). Focus: The fund is specifically targeted at early-stage biotech and MedTech companies. This is a strong signal of investor confidence in European deep-tech and medical innovation, providing much-needed liquidity for startups facing the "series A crunch." 3. Major Events: Medica &amp; Helsinki Summit Europe hosted two pivotal industry gatherings this week, driving networking and partnership announcements. MEDICA 2025 (Düsseldorf, Nov 17–20): One of the world's largest medical trade fairs concluded yesterday. Key themes this year included "Hospital 4.0," sustainable manufacturing, and the integration of generative AI into clinical workflows. MedTech Innovation Helsinki Summit (Nov 19): This high-profile summit focused on bridging the gap between Nordic innovation and global capital. Highlight: The event featured a pitch competition with a €300,000 investment prize, hosted in partnership with Global Medical Solutions and Samsung Medical. The event underscored the growing role of corporate venture capital (CVC) in the European market. 4. Product &amp; Corporate Moves Zydus Lifesciences (CE Mark): While announced just prior to this week, the industry is currently digesting the impact of Zydus' subsidiary, Amplitude Surgical, receiving the CE Mark for its "Andy" robotic surgical system. This clears the way for a new competitor in the European orthopaedic robotics market, challenging established US players. Global M&amp;A Ripples: The sector is also reacting to Abbott’s massive $21 billion acquisition of Exact Sciences(announced earlier but dominating discussion at Medica). For European MedTech, this consolidation signals likely intensified competition in the non-invasive cancer diagnostics space across the continent. &nbsp; &gt;&gt;&gt;&nbsp; &nbsp; European HealthTech (digital health, data and AI) developments for the week of November 17–21, 2025 are detailed below. While the broader medical device sector is focused on hardware delays, the HealthTech conversation this week shifted sharply toward data access and AI liability. 1. Regulation &amp; Policy: A Double-Edged Sword for AIThe biggest structural shift for European HealthTech occurred on Wednesday, November 19, with the European Commission's "Digital Omnibus" proposal. The "Data Unlock" (GDPR Reform): Beyond the AI Act delay, the most critical update for HealthTech is a proposed change to GDPR. The Commission wants to classify "training AI models" as a "legitimate interest." Why this matters: Currently, HealthTech startups often struggle to use patient data to train algorithms without explicit, granular consent. If passed, this amendment could significantly lower the legal barrier for accessing real-world data (RWD) to build predictive models. The Counterpoint (WHO Warning): coinciding with this deregulation push, the World Health Organization (Europe) released a report this week warning of a "regulatory vacuum" regarding AI liability. They cautioned that while tools are being adopted rapidly, it remains unclear who is legally responsible, the software provider or the clinician, when an AI diagnostic tool makes an error. 2. Investment: FemTech &amp; UK Life SciencesWhile mega-rounds were quieter this week compared to earlier in the month (e.g., Qida’s €37M raise was Nov 4), specialized sectors saw fresh activity. Emm (UK) raises €7.7M: Bristol-based FemTech startup Emm secured €7.7M ($9M) in Seed funding on November 19. The Tech: They are developing a "smart menstrual cup" that uses biosensors to monitor health metrics remotely. This highlights a growing trend of "invisible" wearables that passively collect clinical-grade data. UK Government &amp; Sofinnova: As part of a broader life sciences package announced Nov 18, the British Business Bank committed €30 million specifically to Sofinnova’s new fund. This capital is earmarked for high-growth digital and biotech ventures, reinforcing the UK's post-Brexit push to remain a top hub for health innovation. 3. Innovation Highlight: AI in Practice (Ireland) The AI Awards Ireland (Nov 18) provided a look at which HealthTech solutions are gaining traction on the ground right now: Best AI in a Startup: Won by WHYZE Health, a platform that uses AI to match patients with clinical trials using real-world evidence. This addresses a major bottleneck in European pharma: slow patient recruitment. Clinical Efficiency: St. Luke’s Radiation Oncology Network won for an AI tool that automates "contouring" (outlining tumours) for radiation therapy. The system reportedly reduces manual planning time by 50%, a concrete example of AI relieving workforce burnout. 4. Ecosystem &amp; Events European Digital Health Literacy Conference (Aalborg, Nov 17-18): This inaugural conference focused on the "human side" of HealthTech adoption. A key takeaway was the "digital divide", new EU data suggests that while apps are proliferating, elderly adoption remains stalled due to poor UX design, prompting calls for new "age-inclusive" software standards. Danish Tech in Silicon Valley: A delegation of Danish HealthTech startups is currently in Palo Alto (Nov 17-21) for the "Plug and Play" summit, actively seeking US commercial partners to scale European digital solutions transatlantic.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a> &nbsp;

Nelson Advisors

Blog

This Week in European HealthTech and MedTech: 28th Novemb...

What does today's Budget really mean for UK HealthTech an...

Nelson Advisors invited to join the Future Health Intelli...

Nelson Advisors invited to Chair the Health Data and Cybe...

HealthTech M&A Multiples November 2025: Current Trends an...

This Week in European HealthTech and MedTech: 21st Novemb...